Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc, has amended its 2008 co-promotion agreement with Wyeth, now a wholly owned subsidiary of Pfizer. Impax will now detail Lyrica (pregabalin) CV for use as adjunctive therapy for adult patients with partial onset seizures to neurologists effective April 1st. Impax will discontinue detailing Pristiq (desvenlafaxine extended-release tablets).

Impax Labs is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products.

In the US Lyrica is indicated for the management of post-herpetic neuralgia (PHN), painful diabetic peripheral neuropathy (pDPN), fibromyalgia, and as adjunctive therapy for adult patients with partial onset seizures.